Featured Story | By Ben Adams As Moderna, Pfizer and BioNTech have this month been busy releasing early data out of their COVID-19 vaccine programs, AstraZeneca is now joining the July data drop. read more |
| |
|---|
|
Top Stories By Nick Paul Taylor Pfizer and BioNTech have shared (PDF) phase 1/2 data suggesting their COVID-19 vaccine triggers stronger CD8 T-cell responses than Moderna’s rival candidate. Four-fifths of subjects who received BNT162b1 had vaccine-induced CD8 T-cell responses and researchers classed most of the responses as strong. read more By Amirah Al Idrus Given drugmakers’ reliance on their R&D organizations, you might expect the companies with the biggest R&D budgets to match those paying their chief scientists the most. But that theory doesn’t hold up. For starters, Regeneron’s George Yancopoulos who topped this list with $20.7 million, but the company’s research spend didn’t even make it into 2019’s top 10. read more By Patheon, by Thermo Fisher Scientific Ensuring cohesion between drug substance chemists & drug product formulators is critical to manage risks & maximize rewards of transforming less soluble & bioavailable molecules into effective drugs. read more By Ben Adams A U.K. biotech has seen its shares skyrocket on new data from its experimental treatment in hospitalized COVID-19 patients, but it’s too early for game-changer cliches. read more By Nick Paul Taylor GlaxoSmithKline has handed CureVac £234 million ($294 million) to collaborate on the use of mRNA to prevent and treat infectious diseases. The deal, which excludes CureVac’s COVID-19 vaccine, sets GSK up to source up to five clinical-phase mRNA-based vaccines and monoclonal antibodies. read more By Amirah Al Idrus After a game of executive musical chairs, David Meeker, M.D., is taking the helm of obesity-focused Rhythm Pharmaceuticals. He takes over from Hunter Smith, the biotech’s chief financial officer who had been filling in as president and CEO since March after former chief Keith Gottesdiener stepped down. read more By Arlene Weintraub University of Pittsburgh researchers found a correlation between the cell-surface protein LAG-3 and another protein called ADAM-10 that could portend a poor response to PD-1 checkpoint blocking drugs in cancer. They believe their findings could improve ongoing efforts to target LAG-3 in cancer. read more By Conor Hale The FDA authorized its first COVID-19 diagnostic test for use with pools of samples in a move to let laboratories conserve resources by evaluating groups of people at once. read more |  | Capture more value with your biotech equity Strategic planning for your early stage equity can result in a tax savings of up to $10 million as Qualified Small Business Stock. Harness works with serial scientific co-founders from top academic institutions and high growth company executives to find specialized financial advisors to help them capture more equity value. Get started now. |
Resources Sponsored by: Lonza Pharma & Biotech A novel spray-dried dispersion platform has been developed to faciliate high drug load applications Sponsored by: Florence Complimentary Download: How to connect to study sites remotely via the Electronic Investigator Site File (eISF) to streamline clinical operations. Insights from the largest eISF network in the world. Sponsored by: PRA Health Sciences Collaboration across the industry will be key to meeting the demands of the RACE Act and ensuring pediatric patients receive the care and treatments they need. Sponsored by: Cytiva On-demand video: fuel gene therapy development and production with modern AAV workflows. With today’s rapidly evolving environment, we have created this five-part content series to highlight pressing issues and topics that are more pertinent today than ever before. Sponsored by: Cambrex The industry trend of outsourcing to CDMOs continues. With more services, capabilities, facilities, and employees than ever before, our experts have contributed more articles to our biggest eBook yet. Sponsored by: EVERSANA How predictive analytics and machine learning have the potential to transform healthcare by predicting “Patient Switching Behaviors.” Sponsored by: Recro Gainesville Wurster processing is a versatile technique for developing and manufacturing multiparticulates for modified release dosage forms. Read this whitepaper to determine whether Wurster processing is the right option for your project. Sponsored by: Systech Get an inside look… Merck shares its next-generation approach to supply chain protection with new digital platforms, including Blockchain. Sponsored by: Automation Anywhere Built on advances in Artificial Intelligence (AI), data mining, and information integration into various systems at 100% accuracy, the new era of intelligent automation is integral to life sciences for devising new treatments faster and at a lower expense. Sponsored by: Catalent Learn about a real-world example of how clinical supply management expertise was applied to overcome inventory challenges for a complex, global study. Sponsored by: Catalent Whether a study is simple or highly complex, forecasting and simulation reports serve as data driven communication tools to help minimize risks and keep the study on track. Learn more about forecasting solutions for informed decision making and supporting contingency planning for clinical study. Sponsored by: Catalent Learn how to drive excellence within the forecasting process and utilize forecasting throughout the clinical study to better plan clinical supply budgets and project timelines. Explore how to identify potential supply-related issues before they can negatively impact your study. | 
